Francois Lebel - Jun 21, 2022 Form 4 Insider Report for SPECTRUM PHARMACEUTICALS INC (SPPI)

Role
Chief Medical Officer
Signature
/s/ Keith M. McGahan, attorney-in-fact for Francois Lebel
Stock symbol
SPPI
Transactions as of
Jun 21, 2022
Transactions value $
-$10,507
Form type
4
Date filed
6/23/2022, 08:24 PM
Previous filing
Apr 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SPPI Common Stock, $0.001 par value Award $0 +405K +160.4% $0.00 658K Jun 21, 2022 Direct F1
transaction SPPI Common Stock, $0.001 par value Sale -$4.91K -6.1K -0.93% $0.81 651K Jun 22, 2022 Direct F2
transaction SPPI Common Stock, $0.001 par value Sale -$5.59K -6.67K -1.02% $0.84 645K Jun 23, 2022 Direct F2
holding SPPI Common Stock, $0.001 par value 7.23K Jun 21, 2022 By 401(k) plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SPPI Stock Option (Right to Buy) Award $0 +1.49M $0.00 1.49M Jun 21, 2022 Common Stock 1.49M $0.63 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc.'s ("Spectrum") board of directors on January 27, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the "Plan") under which the restricted stock unit was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
F2 All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer.
F3 The option grant was approved by Spectrum's board of directors on January 27, 2022, subject to stockholder approval of the Plan under which the option was granted. Spectrum's stockholders approved the Plan on June 21, 2022.
F4 One third of the aggregate amount of option shares shall vest on each of January 27, 2023, 2024 and 2025, respectively.